Clene to File Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting

summarizeSummary

Clene Inc. announced positive feedback from the FDA, indicating its data may support an accelerated approval New Drug Application (NDA) for its ALS drug candidate, CNM-Au8, which the company plans to submit in Q3 2026.

check_boxKey Events

• FDA Greenlights Accelerated Approval Pathway

  The FDA stated that Clene's proposed data may be capable of supporting an accelerated approval New Drug Application (NDA) for CNM-Au8 for the treatment of ALS.

• NfL Acknowledged as Potential Surrogate Endpoint

  The FDA noted that Neurofilament light (NfL) could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval for CNM-Au8.

• NDA Submission Planned for Q3 2026

  Clene Inc. intends to submit its New Drug Application (NDA) for CNM-Au8 to the FDA in the third quarter of 2026.

• Phase 3 Confirmatory Study to Commence in Q1 2027

  The company is conducting a Phase 3 confirmatory study for CNM-Au8, which it intends to commence in the first quarter of 2027.

auto_awesomeAnalysis

This announcement is a critical positive development for Clene Inc., especially given the company's recent disclosure of substantial doubt about its ability to continue as a going concern. The FDA's indication that Clene's data may support an accelerated approval pathway for its ALS drug candidate, CNM-Au8, and the acknowledgment of Neurofilament light (NfL) as a potential surrogate endpoint, significantly de-risks the regulatory path. An accelerated approval could bring the drug to market much faster, providing a potential revenue stream that is vital for the company's long-term viability. Investors should closely monitor the planned NDA submission in Q3 2026 and the subsequent FDA review process, as this represents a major step towards commercialization and could fundamentally alter the company's financial outlook.